Bristol-Myers Squibb Co (BRM) Stock Price & News

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia

About Bristol-Myers Squibb Co

CEOქრის ბერნერი

Employees32,5 ათ.

Founded1887

Headquartersნიუ-იორკი, ნიუ-იორკის შტატი, ამერიკის შეერთებული შტატები

SectorPharmaceutical industry

Websitebms.com

Revenue

Net income

All values in USD	სექ. 2025	დეკ. 2025	მარ. 2026	ივნ. 2026
Revenue	12,22 მლრდ.	12,50 მლრდ.	11,49 მლრდ.	12,97 მლრდ.
Cost of goods sold	3,31 მლრდ.	3,51 მლრდ.	3,41 მლრდ.	3,71 მლრდ.
Cost of revenue	3,31 მლრდ.	3,51 მლრდ.	3,41 მლრდ.	3,71 მლრდ.
Research and development expenses	2,43 მლრდ.	2,56 მლრდ.	2,24 მლრდ.	2,54 მლრდ.
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,79 მლრდ.	2,09 მლრდ.	1,61 მლრდ.	1,82 მლრდ.
Operating expense	5,05 მლრდ.	5,47 მლრდ.	4,28 მლრდ.	4,80 მლრდ.
Total operating expenses	8,36 მლრდ.	8,98 მლრდ.	7,69 მლრდ.	8,51 მლრდ.
Operating income	3,86 მლრდ.	3,52 მლრდ.	3,80 მლრდ.	4,46 მლრდ.
Other non operating income	529,00 მლნ.	544,00 მლნ.	125,00 მლნ.	106,00 მლნ.
EBT including unusual items	3,11 მლრდ.	1,47 მლრდ.	3,24 მლრდ.	4,09 მლრდ.
EBT excluding unusual items	4,07 მლრდ.	3,86 მლრდ.	3,65 მლრდ.	4,35 მლრდ.
Income tax expense	919,00 მლნ.	384,00 მლნ.	561,00 მლნ.	770,00 მლნ.
Effective tax rate	29,51%	26,12%	17,32%	18,84%
Other operating expenses	-	-	-	-
Net income	2,20 მლრდ.	1,09 მლრდ.	2,68 მლრდ.	3,32 მლრდ.
Net profit margin	18,01%	8,69%	23,30%	25,57%
Earnings per share	1,63	1,26	1,58	2,04
Interest and investment income	161,00 მლნ.	148,00 მლნ.	104,00 მლნ.	101,00 მლნ.
Interest expense	-482,00 მლნ.	-432,00 მლნ.	-406,00 მლნ.	-403,00 მლნ.
Net interest expenses	-321,00 მლნ.	-284,00 მლნ.	-302,00 მლნ.	-302,00 მლნ.
Depreciation and amortization charges	-	-	-	-
EBITDA	4,91 მლრდ.	4,54 მლრდ.	4,41 მლრდ.	5,08 მლრდ.
Gain or loss from assets sale	-9,00 მლნ.	-	-34,00 მლნ.	-142,00 მლნ.

Ask anything